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tube to find their effect upon the several microbic genera; then to find the doses which were tolerated by laboratory animals; and finally, if that seemed to be warranted, their effect upon the infections, natural or experimental, of animals and man.
For several years this work yielded no clear leads, but at the end ol 19a2 a surprising result was obtained, when a red azo dye combined with a sulphonamide radical was under investigation. This compound had been synthesized some years earlier by the I. G. Farbenindustrie chemists, Fritz Mietsch and Joseph Klarer, in the hope that it would prove a valuable 'fast' dye for treating leather. It became known later as 'Prontosil R ubrum '. Although preliminary tests with it had shown little bacterial activity vitro, it seemed to have some protective power against streptococcal infections in the mouse. Its toxicity was also low for mice.
In view of these findings it seemed worth while to repeat the mouseprotection test, using 26 animals and a test culture of haemolytic streptococci which was always fatal when injected into the peritoneum. Fourteen of them were kept as controls and died within 4 days-most of them on the second day. The other 12 were treated with a single dose of the red dye (by stomach tube*) I f hours after the streptococci. All remained in good condition during the 7 days they were under observation.
Three years elapsed before this striking result was reported in the Deutsche Medizinische W o c h e n s c h r i f t for 1935 (vol. 61). It is not clear whether publication was delayed until conclusive evidence was available as to the effect of Prontosil on human infections, or whether Domagk (and possibly other workers) had difficulty in repeating the 1932 experiment in its perfection. In retrospect it seems probable that any such difficulties may have been chiefly due to the fact that strains of streptococci used by different workers varied in their susceptibility to Prontosil; and that more than one dose of the drug was often required to protect the mice indefinitely.
However that may be there is no doubt that Domagk's discovery had opened up an immense field for therapeutic advance. Ever since the haemo lytic streptococcus had been recognized as a distinct bacterial species by the work of Schottmuller in Germany and of Howard Brown in Baltimore it had been known as one of the chief enemies of the human race. It played a major role in the heavy and tragic mortality of puerperal and acute rheumatic fevers, of countless septicaemic and cellulitic conditions resulting from war wounds (and civilian injuries-including burns), as well as of erysipelas and the numerous acute inflammatory conditions of the respiratory tract and the ear-the latter being chiefly responsible for the immeasurable miseries of deafness.
In all this large field of suffering and disease Domagk's discovery brought a * I had not previously encountered this trick of administering a drug to mice. Nor have I since. It presented some difficulties at first, but after a little practice these were soon overcome, and the animals seemed to suffer little inconvenience. I have also not met with comparable records in which a protective drug was given to some mice by stomach tube and to others subcutaneously or intra venously. new hope. Reports soon came in from all over the world, of rapid recoveries and diminished mortality in all these conditions.
But that was only a beginning. Domagk's experiment prompted an immediate enquiry in many laboratories as to whether Prontosil (or sub stances nearly related to it) could exert a similar chemo-therapeutic effect upon human diseases caused by bacteria quite different from haemolytic streptococci. The result was surprising. In England it was quickly found (after preliminary mouse-protection tests) that cerebro-spinal meningitis (which had usually proved fatal) could readily be arrested and cured. Pneumonia, too,-'the captain of the men of death'-was similarly brought under control. And the dreaded venereal disease, gonorrhoea, usually cleared up in a few days.
Apart from these important therapeutic gains laboratory work on Prontosil soon brought new understanding of the means by which that drug achieved its results. Trefouel and his colleagues at the Pasteur Institute in Paris quickly realized that the azo component was probably dissociated in vivo, with liberation of the sulphonamide radical to which it was linked; and that this latter was largely responsible for the antibacterial effects. Proof of that dissociation was obtained by Fuller at Queen Charlotte's Hospital; and clinical trials at that hospital soon showed that sulphanilamide in strepto coccus-infected patients was roughly comparable with that of the parent Prontosil. That was especially important because sulphanilamide could be produced far more cheaply than Prontosil.
Domagk's success also led to a number of investigations as to how the antistreptococcal effects were produced. Were they due to a specific inhibition of an essential reaction which interfered with some catalytic process in the bacterial cell ? Or were they due, as the observations of Fildes and Woods led them to suppose, to competition for an enzyme associated with an 'essential metabolite' ? Those authors claimed that that essential metabolite was in fact />-amino-benzoic acid, which they regarded as 'so closely related in formula to the essential metabolite that it can fit the same enzyme, and sufficiently unrelated to be devoid of essential metabolic activity' (Fildes 1940) . That new concept could well prove to be of great importance in the search for future chemotherapeutic agents.
It was for his pioneer work in this large field, and his stimulation of other workers, that Domagk was awarded the Nobel Prize for Medicine in 1939. In October of that year he duly acknowledged the notification of that great honour to the Caroline Institute but a few weeks later was obliged by the Nazis then in power to decline the award. (In the interval he had been arrested by the Gestapo. It transpired later that when in 1936 Carl von Ossietsky had been awarded the Nobel Peace Prize Hitler was furious and decreed that no German was to be so honoured in future.)
However, after the war (1947) Domagk was duly given the medal, but, in accordance with the regulations, the prize money had meanwhile reverted to the Foundation's funds so that he was not enabled to receive it.
For some years after the Nobel award Domagk was chiefly engaged upon the chemotherapeutic approach to tuberculosis. In 1944, when the anti biotics were becoming available, the most promising line of attack seemed to be by streptomycin which had been discovered by Waksman in U.S.A. Its use however was limited by the risk of injury to the ear and vestibular apparatus; and also by its tendency to produce resistant strains ol the tubercle bacillus. By 1946 another approach was being pursued. The Swedes had shown the ability of ^-aminosalicylic acid to inhibit the activity of the bacillus, while in England it was found that the same substance helped to delay the emergence of resistant strains.
Meanwhile Domagk had completed a survey of the various sulphonamide derivatives. Only sulphathiazole and sulphathiadiazole (see below) 'On the basis of early inadequate clinical trials in Germany, enthusiastic claims were made, only to die away after an American team reported in 1950 that the hepatic toxicity precluded their general use. Moreover this series was overshadowed by the discovery simultaneously in Switzerland and the U.S.A. (and possibly in other countries) of the present major antituberculosis drug isonicotinic acid hydrazide (isoniazid), the development of which was connected partly with Chorine's (1945) discovery in France that nicotinamide (a pyridine derivative) had some antituberculous activity, and partly (as a chemical stepping-stone) with the thiosemicarbazones, and therefore with Domagk's work. ' Dr H art continues 'Isoniazid is most effective in man when used together with streptomycin or ^-aminosalicylic acid, the combined treatment in correct dosage preventing the emergence of resistant strains to either component drug. Domagk and his co-workers advocated that a thiosemicarbazone should be the companion drug to isoniazid, but they were ill-served by the dosage selected which, while lacking the major toxicity of the early days, was probably too low to prevent resistance with certainty. However, as a result of British work, a different regimen of thiosemicarbazone plus isoniazid has been shown to be a cheap and effective treatment, with little toxicity, in certain populations, though possibly not equally so in all; hence the restoration of the thiosemicarbazones to favour is provisional and at present only limited in extent. ' Dr H art also adds a footnote to the above 'I believe that the steps were: (1) Nicotinamide was active but not nicotinic acid, and therefore the activity was not a vitamin effect; (2) Attention was thus focused on pyridine deriva tives; (3) Replacement of the substituted benzene ring of j^-acetamidobenzaldehyde thiosemicarbazone by a pyridine ring, resulting in the pyridine analogues, nicotinaldehyde thiosemicarbazone and isonicotin aldehyde thiosemicarbazone. To make the latter compound a process involving pyridine carboxylic acid derivatives was used, and one intermediate was isonicotinic acid hydrazide, i.e. isoniazid. In this sense the thiosemicarbazones were chemical stepping-stones, but the final step was made by the U.S. and Swiss chemists, although for all I know the Germans and Russians may have got part or all the way.'
During the last few years of his active life Domagk became increasingly interested in the problem of cancer, hoping that a substance might be found which would be effectively 'cytostatic' for tumour cells, i. The ethyleneimine is abbreviated in the formulae.
and discussed their possible mode of action. There is no doubt that these drugs, and a later one developed from them, namely 'Trenimon' (3 above) showed some clinical successes which are not unlike those with a number of other alkylating agents. As Domagk himself, as a true medical scientist, wrote: 'One should not have too great expectations of the future of cytostatic agents. This may also carry a prophecy, because the methods of chemo therapy of cancers of the future may not follow too closely the effect of the sulphonamides against bacterial invaders but the more subtle ones of reversal and immunological control.'
In addition to his award of the Nobel Prize for Medicine Domagk was the recipient of many honours. Among them were the Fellowship of the Royal Society (1959) ; that of the Kaiserlich-Leopoldinisch-Carolinischen Academy; The German Academy of Naturforscher; as well as that of Literature, and honorary doctorates of several Universities. W hat especially pleased him was the award of the Paul Ehrlich gold medal, and that of the Cameron Medal from the University of Edinburgh.
His colleagues of the Bayer Foundation wrote of him after his death 'As intensively as Domagk devoted himself to the goal of pure medicine to help mankind in disease he took every opportunity to speak for peace and under standing amongst nations. In spite of his great honours he was a very modest and charming person. He had an open mind to all cultural activities and was a friend and protege of modern art, and loved nature.' Domagk married Gertrud Strube in 1925 and had three sons and one daughter (whom, in the very early days of work on Prontosil he treated for a very severe streptococcal infection-with a happy result). 
